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Abstract
Nitric oxide (NO) is an important mediator in both health and
disease. In addition to its effects on vascular tone and platelet
function, it plays roles in inflammation and pain perception that may
be of relevance in osteoarthritis. Many patients with osteoarthritis
take nonsteroidal anti-inflammatory drugs (NSAIDs) long term for
pain control. Over recent years concern has been raised about the
possible cardiovascular side effects of NSAIDs. The reasons for this
possible increased cardiovascular risk with NSAIDs are not yet
entirely clear, although changes in blood pressure, renal salt handling
and platelet function may contribute. Recently, drugs that chemically
link a NSAID with a NO donating moiety (cyclo-oxygenase-inhibiting
NO-donating drugs [CINODs]) were developed. NO is an important
mediator of endothelial function, acting as a vasodilator and an
inhibitor of platelet aggregation, and having anti-inflammatory proper-
ties. The potential benefits of CINODs include the combination of
effective analgesic and anti-inflammatory actions with NO release,
which might counterbalance any adverse cardiovascular effects of
NSAIDs. Effects of CINODs in animal studies include inhibition of
vasopressor responses, blood pressure reduction in hypertensive
rats and inhibition of platelet aggregation. CINODs may also reduce
ischemic damage to compromised myocardial tissue. In addition,
endothelial dysfunction is a recognized feature of inflammatory
arthritides, and therefore a drug that might provide slow release of
NO to the vasculature while treating pain is an attractive prospect in
these conditions. Further studies of the effects of CINODs in
humans are required, but these agents represent a potential exciting
advance in the management of osteoarthritis.
Introduction
Recently issued guidelines for the management of
osteoarthritis [1] have emphasized the use of lifestyle advice,
weight loss, and exercise as first-line interventions in the
management of osteoarthritis, followed by the addition of
paracetamol or topical nonsteroidal anti-inflammatory drugs
(NSAIDs). However, many patients with osteoarthritis will
require the use of systemic NSAIDs for control of their pain.
Recently, NSAIDs (both traditional and cyclo-oxygenase
[COX]-2 selective) were linked to an increased incidence of
cardiovascular events, at least in patients at increased
baseline cardiovascular risk [2-5]. The degree of the risk
associated with the various NSAIDs and the mechanisms
underlying the link with cardiovascular events are still being
investigated in large clinical trials. Findings to date have had a
major influence on the use of these drugs in the management
of chronic arthritic conditions, with regulatory authorities
advising against the use of these drugs in patients with
known cardiovascular disease or who are at high cardio-
vascular risk. However, many patients rely on NSAIDs to
achieve adequate pain relief, and the risk/benefit ratio must
be carefully considered when deciding whether to prescribe
these agents. Options to ameliorate or counteract the risk
associated with chronic use of NSAIDs in patients with
arthritis would be welcome.
Nitric oxide (NO) is an important endogenous mediator of
vasodilatation, also having effects on platelet function, inflam-
mation, and pain perception. NO is also released from some
drugs, historically nitrates, but more recently other agents that
have been specifically designed to contain a NO moiety,
which is released enzymatically in tissues and plasma. One
approach that might ameliorate the cardiovascular risk
associated with NSAIDs would be to use NSAIDs that also
release NO, namely the cyclo-oxygenase inhibiting nitric oxide
donating drugs (CINODs). NO may also have other effects
on the vasculature, including improvements in endothelial
function and vascular tone, as well as effects on platelet
aggregation. The link between atherosclerosis and chronic
inflammation is increasingly recognized, with suggestions
made that systemic inflammatory conditions such as
rheumatoid arthritis also affect the vasculature, leading to a
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greater incidence of cardiovascular events. Data reported
thus far suggest that NO may have a complex mixture of
positive and negative effects on inflammation and pain in
osteoarthritis; therefore, the role played by CINODs in this
condition remains to be determined.
In this article we review the importance of NO, and the
effects of NSAIDs on blood pressure and endothelial
function, and we explore the possible roles played by NO and
CINODs in osteoarthritis.
Endothelium and nitric oxide
Historical perspective
NO-releasing drugs have been in use for about 150 years
and now include the organic nitrates, sodium nitroprusside
and nicorandil. The first organic nitrate, glyceryl trinitrate
(GTN), was originally synthesized in 1847 by the Italian
chemist Ascanio Sobrero. He observed that small amounts of
GTN placed on the tongue caused a violent headache, which
led Constantin Hering to pursue the development of GTN as
a homeopathic remedy for headache [6]. In 1867 the British
physician Lauder Brunton observed that the related
compound amyl nitrite could be used to provide pain relief in
angina. In 1879, William Murrell reported that a 1% solution
of GTN was effective as both an acute antianginal agent and
as prophylaxis against angina [7], and the use of GTN and
other nitrates was later extended to the management of
severe hypertension and heart failure. Even in these early
years it was clear that nitrate therapy was hampered by the
development of nitrate tolerance, although the mechanisms
for this were not understood and indeed are still being
elucidated today [8].
Until the late 20th century, little was understood about the
mode of action of the nitrate drugs beyond the fact that they
appeared to cause vasodilatation through vascular smooth
muscle relaxation. However, in 1977 the pharmacologist
Ferid Murad and colleagues [9] showed that nitrate
application caused stimulation of soluble guanylyl cyclase
derived from rat liver and bovine tracheal smooth muscle. In
turn, this caused an increase in the second messenger
cGMP levels, which caused vascular relaxation. They
suggested that the cGMP activation may occur via NO
because they had also found that NO itself increased
guanylyl cyclase activity [9,10]. Another group, the pharmaco-
logist Robert Furchgott and his colleagues [11,12] showed
that removal of endothelium from the blood vessels prevented
the usual vasorelaxation caused by acetylcholine. This
supported the importance of the vascular endothelium in
vasorelaxation. Those investigators also showed that soluble
guanylate cyclase could be activated by NO [12] and agreed
with Murad’s theory that NO could be the mediator of the
action of nitrovasodilators on vascular smooth muscle.
Furchgott and coworkers [13] also identified a vascular
relaxant factor, which they called endothelial-derived relaxing
factor, and which they thought might mediate the vascular
relaxation in response to substances such as bradykinin,
histamine, ATP, and ADP.
In 1986 it was first proposed that endothelial-derived relaxing
factor and NO were the same molecule, and this was proven
the following year in series of experiments reported by Ignarro
[14] and Moncada [15] and their colleagues. Although most
evidence points to NO release as being the mechanism of
vasodilatation caused by nitrates, data showing a
discrepancy between GTN-dependent vasodilatation and NO
formation have called this concept into question [16].
Mode of action of nitric oxide
It is now known that NO activates guanylyl cyclase in vascular
smooth muscle, leading to increased production of cGMP.
This activates a cGMP-dependent protein kinase and leads to
phosphorylation of proteins that are involved in the regulation
of intracellular calcium levels. There is a resultant reduction in
cytosolic calcium levels, and this leads to relaxation of
vascular smooth muscle and hence vasodilatation. In addition
to its vascular effects, NO also has inhibitory effects on
platelet aggregation and effects on inflammation and pain
perception. Endogenous NO is produced by nitric oxide
synthase (NOS) from the substrate L-arginine (Figure 1).
Different isoforms of NOS exist, including constitutive forms
that provide continuous low-level production of NO and an
inducible form, the expression of which increases upon
stimulation by cytokines or other activators, leading to the
production of large amounts of NO. The types of NOS are
classified as endothelial NOS (eNOS; NOS3), which
regulates vascular function; inducible NOS (iNOS; NOS2),
which is present in vasculature but is also involved in immune
responses; and neuronal NOS (nNOS; NOS1), which is
present predominantly in the peripheral and central nervous
systems. eNOS and nNOS are the constitutive forms of NOS.
One example of a condition in which lack of NO plays an
important role is primary pulmonary hypertension [17]. This
disease is thought to be due to an imbalance between
vasodilating and vasoconstricting substances, and reduced
NO bioavailability in the pulmonary circulation has been
identified. Similarly, lack of NO is involved in the patho-
genesis of pulmonary hypertension secondary to sickle cell
disease. Hemolysis causes the release of hemoglobin from
erythrocytes, and this free hemoglobin binds with NO,
reducing NO bioavailability and resulting in the formation of
reactive oxygen species, which are potentially damaging to
the pulmonary vasculature. In addition, arginase is released
from the damaged erythrocytes, reducing the availability of
arginine, which is the substrate for NO production by NOS
[18]. Although drugs that cause cGMP activation, such as
phosphodiesterase-5 inhibitors, or therapy with NO itself or
NO-releasing drugs have had some beneficial effects in the
management of pulmonary hypertension, the therapeutic
benefits of arginine for pulmonary hypertension remain
controversial [19,20].Page 3 of 12
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Osteoarthritis and nitric oxide
Mechanisms of osteoarthritis
The clinical manifestations of osteoarthritis stem mostly from
the changes that occur within articular cartilage. Cartilage
structure consists of chondrocytes surrounded by an extra-
cellular matrix of macromolecules, notably proteoglycans
(particularly glycosaminoglycans) and collagen. Glycosamino-
glycans are responsible for the high water binding capacity of
cartilage, a physical property that is essential to making
cartilage resistant to compression, durable to shock loads
and smooth-surfaced in health. Initiating factors in the
degeneration of cartilage - the primary finding in osteoarthritis -
are still not fully understood. Abnormal load on normal
cartilage or normal load on abnormal cartilage may account
for the degeneration, but they do not describe the details and
neither do they address the variation in presentation of
osteoarthritis, even within individuals. In early osteoarthritis
there is evidence for increased synthetic activity of chondro-
cytes. Progression of osteoarthritis is accompanied by
decreased proteoglycans and collagen synthesis, disrupting
the mechanical strength of cartilage. Erosion reduces joint
space and subchondral bone becomes more vascular and
cellular, particularly at points of greater mechanical stress.
Inflammation and osteoarthritis
The absence of systemic features of inflammation or local
findings such as the presence of neutrophils within synovial
fluid have traditionally prevented osteoarthritis being con-
sidered within the inflammatory arthropathies. However, joints
acutely affected by osteoarthritis may exhibit all of the clinical
signs of inflammation [21]. Therapies that reduce the inflam-
matory response, such as NSAIDs and intra-articular steroid,
provide symptomatic relief in osteoarthritis. Chondrocytes,
which are the cellular occupants of cartilage and therefore
are central to maintaining the integrity of the matrix, may
produce inflammatory mediators (including cytokines) under
conditions of stress. Such cytokines, including IL-1 and tumor
necrosis factor-α, stimulate the production of prostaglandins
and NO. The complex interplay between these mediators and
the microenvironment of the cartilage matrix may direct
chondrocytes toward catabolism or anabolism [22].
These and other observations indicate that osteoarthritis is at
least partly an inflammatory process. However, disease-
modifying osteoarthritis drugs have thus far been an elusive
goal of research in osteoarthritis. The success of biologic
therapies such as tumor necrosis factor-α antagonists in
rheumatoid arthritis has stimulated hope that targeting
cytokine modulators may also be useful in osteoarthritis.
Progress in this area will be dependent on many other issues.
One is a better understanding of how the inflammatory
activity in osteoarthritis fits in with other recognized risk
factors such as increasing age, obesity, previous joint
damage and genetics. Another is how to achieve acceptable
risk/benefit ratios from the treatments with respect to their
safety and economics.
Inducible nitric oxide synthase expression in arthritis
Expression of iNOS has been identified in many human cell
types, but chondrocytes were among the first to be recog-
nized [23]. Many additional pieces of evidence link NO to the
pathogenesis of osteoarthritis. Osteoarthritic joints exhibit
elevated NO production as well as increased amounts of
other inflammatory mediators. Patients with osteoarthritis
(and rheumatoid arthritis) exhibit markers of enhanced NO
production in their synovial fluid, serum, and urine, including
increased levels of NO, increased circulating nitrites and
nitrates, and upregulation of iNOS expression in chondro-
cytes [24]. Most human cells that are capable of iNOS
expression require multiple synergistically active cytokines to
induce NO synthesis. Human chondrocytes, however, differ
significantly and may be induced by a single cytokine such as
IL-1 [25]. iNOS expression in osteoarthritis occurs mainly in
chondrocytes, whereas in rheumatoid arthritis it occurs
predominantly in synovial lining cells, endothelial cells,
chondrocytes, infiltrating mononuclear cells, and synovial
fibroblasts [25,26]. Constitutive isoforms of NO synthase are
also observed in synovial lining and vascular smooth muscle
from osteoarthritic joints [27].
Effects of nitric oxide in joints
Much of the in vitro work on the effects of NO has been
carried out in environments with normal oxygen tension,
whereas cartilage is an avascular tissue with low oxygen
tension. Caution may therefore be needed in extrapolating the
results  in vivo. Within the context of osteoarthritis, NO
appears mostly to be a proinflammatory and destructive
mediator. However, NO is also a mediator of normal physio-
logical responses in the body and is produced by chondro-
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Figure 1
Production of nitric oxide. NADPH, nicotinamide adenine dinucleotide
phosphate; NO, nitric oxide; NOS, nitric oxide synthase.cytes from normal cartilage. Therefore, NO generated by
constitutive NOS enzymes may have beneficial effects such
as improved blood flow through vasodilatation, but under
different circumstances, at higher concentrations produced
by iNOS, NO may enhance chondrocyte death and suppress
the synthesis of the cartilaginous matrix. One important factor
may be the NO concentration within the microenvironment of
the cartilage. Constitutive NOS enzymes generate NO at the
picomolar level, whereas iNOS is several orders of magnitude
more active. At higher concentrations the effects of NO are
mediated through reactive oxygen species, which modulate
protein activity through S-nitrosylation of their cysteine
residues. Proteins thus affected include transcription factors,
transforming growth factor-β, insulin-like growth factor-I,
signaling kinases, ion channels, and matrix metallo-
proteinases. Higher NO concentrations also lead to the
formation of peroxynitrite, a reactive mediator formed by the
reaction of superoxide with NO, which may have diverse
negative effects on protein and cell function [28]. NO may
therefore have a mixture of positive and negative effects in
relation to inflammation in osteoarthritic joints.
Joint pain and nitric oxide
Joint pain is the main symptom of osteoarthritis, and relief of
pain is the mainstay of current therapies. Pain fibers are
present throughout all parts of synovial joints except articular
cartilage, although in advanced osteoarthritis the articular
cartilage becomes partially innervated and vascularized. The
earliest pathological changes in osteoarthritic joints are
probably subclinical [29], but there is also much variability in
the symptoms associated with more advanced changes in
arthritic joints between patients, in different joints in the same
patient, and in individual joints over time.
The role of NO in pain is complex because it is thought to
have both positive and negative effects on pain perception.
Low level production of NO by the constitutive forms of NOS
may relieve pain by increasing vasodilatation and improving
circulation as well as by reducing nerve irritation and
inflammation  per se. There is some evidence that this
pathway of NO production is disrupted in abnormally loaded
joints [30]. Conversely, increased NO production after
activation of iNOS by inflammatory cytokines can increase
pain perception. In rat models, it has been shown that it is
possible to reduce pain in a vascular pain model by infusing
NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of
NOS, and to restore the pain by infusing the NO donor
sodium nitroprusside, suggesting that the pain is mediated by
NO [31]. Similarly, in another study [32] infusion of L-NAME
prevented hyperalgesia induced by peroxynitrite.
In osteoarthritic joints, NO could conceivably reduce pain by
several different mechanisms [33]. Improved blood flow
secondary to vasodilatation may restore oxygen, growth
factors, and nutrients to the synovium and subchondral bone.
Nerve ischemia, leading to abnormal nerve membrane
potential and conduction, is also improved by vasodilatation.
Through the cGMP pathway, NO opens potassium channels
and reduces calcium influx from calcium channels.
Consequent hyperpolarization of the nerve-cell membrane
blocks pain transmission. Further studies in humans are
needed if we are to understand better the therapeutic
possibilities of NO donation in the management of joint pain.
Nonsteroidal anti-inflammatory drugs and
osteoarthritis
NSAIDs work by blocking prostaglandin synthesis, largely by
inhibiting the cyclo-oxygenase (COX) enzymes, which
catalyze the conversion of arachidonic acid to prostaglandins
and thromboxane. COX inhibition has anti-inflammatory,
analgesic, and antipyretic effects. There are two main
isoforms of the COX enzyme: COX-1 and COX-2. The former
is constitutively expressed in most body cells and is thought
to have homeostatic functions in tissue maintenance,
whereas COX-2 is inducible, being activated by cytokines
released from inflammatory cells, such as tumor necrosis
factor-α and IL-1, and leads to the production of inflammatory
mediator prostaglandins. Most of the desired effects of
NSAIDs (for example, their anti-inflammatory effects) there-
fore occur via COX-2 inhibition, whereas the unwanted
adverse effects such as gastrointestinal damage largely
occur via COX-1 inhibition, especially inhibition of production
of the gastric mucosal protectant prostaglandins PGI2 and
PGE2. The COX-2 selective inhibitors were designed to have
similar anti-inflammatory and analgesic properties to the
nonselective NSAIDs but with a lower incidence of
gastrointestinal adverse effects such as bleeding and ulcer
disease. Indeed, this has proved to be the case in meta-
analyses of clinical trials of COX-2 selective inhibitors versus
nonselective NSAIDs [34,35].
Nonsteroidal anti-inflammatory drugs and
cardiovascular risk
When it was first noted that increased cardiovascular risk may
be associated with rofecoxib, one proposed mechanism was
that COX-2 inhibitors may cause an imbalance of pro-
thrombotic and antithrombotic prostaglandins favoring
thrombosis, because COX-2 inhibitors reduce production of
prostacyclin by the endothelium, but they do not affect the
COX-1 dependent production of thromboxane by platelets.
However, more recent data suggest that although rofecoxib is
probably associated with a greater risk for cardiovascular
disease than other NSAIDs, the other COX-2 inhibitors
probably have a similar risk to that of most of the traditional
NSAIDs. Other mechanisms not specific to COX-2 inhibitors
are therefore likely to be important. For example, a recent
study showed that both COX-2 inhibitors and traditional
NSAIDs upregulate vascular NADPH (nicotinamide adenine
dinucleotide phosphate) oxidases and uncouple eNOS,
leading to endothelial dysfunction [36]. Further clinical studies
are ongoing to establish the extent of cardiovascular disease
associated with both COX-2 inhibitors and traditional NSAIDs.
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pressure: roles of nitric oxide and
cyclo-oxygenase-2
Early atherosclerotic lesions are thought to be partly
influenced by flow patterns and forces exerted on the vessel
walls. In animal models, steady laminar shear stress induces
the upregulation of both eNOS and COX-2 [37]. NO
produced by the vascular endothelium is thought to have an
important influence on vascular tone and hence blood
pressure. Indeed, intravenous infusion of the NO synthase
inhibitor  NG-monomethyl-L-arginine (L-NMMA), increases
blood pressure in human volunteers [38]. Strategies to
donate NO may therefore help to lower blood pressure. One
example of a drug in which this strategy has been employed
is the β-blocker nebivolol. In addition to its β1-receptor
antagonist properties, nebivolol also activates eNOS and may
stimulate the expression of eNOS, leading to increased NO
production. Although nebivolol has effects on blood pressure
similar to those of other β-blockers (for instance, atenolol
[39]), it has different hemodynamic effects. For example,
unlike atenolol, it causes vasodilatation in the human forearm
when it is infused intra-arterially, and this effect can be
blocked by the co-administration of L-NMMA, which suggests
that it is NO dependent [40]. Nebivolol also improves
endothelial function in hypertensive patients [41] and
reduces arterial wave reflection, thus lowering central blood
pressure more than atenolol [42,43].
Nonsteroidal anti-inflammatory drugs and
blood pressure
Even small differences in blood pressure can have major
influences on outcome. It has been estimated that a 5 mmHg
lower usual diastolic blood pressure leads to about a 40%
reduction in risk for stroke and a 25% reduction in risk for
coronary heart disease [44,45]. NSAIDs have variable effects
on blood pressure, but several of them appear to increase
blood pressure, especially in previously hypertensive
individuals. This effect is thought to occur via different
mechanisms, including activation of the renin-angiotensin
system, vasoconstriction due to inhibition of vasodilatory
prostaglandins, sodium and water retention, and production
of vasoconstricting factors including endothelin-1 and
metabolites of arachidonic acid. NSAIDs also interact with
antihypertensive medications, counteracting their antihyper-
tensive effects [46].
In general, treatment with a NSAID or paracetamol tends to
cause a small but significant increase in blood pressure. In
one meta-analysis of largely hypertensive patients [47],
indomethacin and naproxen were associated with the
greatest increases in blood pressure, whereas ibuprofen,
piroxicam, sulindac, and aspirin had negligible effects on
blood pressure. However, in a recent randomized controlled
trial [48], treatment with lumiracoxib led to significantly lower
blood pressure than treatment with ibuprofen in patients with
controlled hypertension.
Overall, both traditional NSAIDs and COX-2 selective
NSAIDs appear to increase blood pressure, but there are
variations between individual agents. In one meta-analysis
[49], the increases in systolic/diastolic blood pressures versus
placebo with traditional NSAIDs were 2.83/1.34 mmHg and
with coxibs (COX-2 selective inhibitors) they were 3.85/
1.06 mmHg. However, much of the elevation in blood
pressure associated with coxibs as a group in this analysis
might have been attributable to the effects of rofecoxib. In a
further study [50], rofecoxib caused increases in systolic and
diastolic blood pressures compared with celecoxib. It was
hypothesized that this may be due to competition between
rofecoxib and aldosterone for metabolism by cytosol
reductase; however, aldosterone levels were similar in both
arms of the study. Interestingly, in patients with hypertension
and osteoarthritis, patients taking β-blockers or angiotensin-
converting enzyme inhibitors had a greater increase in blood
pressure and a higher incidence of peripheral edema with
rofecoxib than with celecoxib, but there were no significant
differences in blood pressure with either coxib in patients
taking calcium channel blockers or diuretics [51]. In another
study [52], among elderly patients with essential hyper-
tension and arthritis, indomethacin increased blood pressure
in those taking enalapril but not in those taking amlodipine.
However, in patients taking lisinopril for hypertension,
celecoxib had no effect on 24-hour ambulatory blood
pressure compared with placebo, with the placebo-corrected
differences in 24-hour ambulatory blood pressure being
1.6/1.2 mmHg (nonsignificant) [53].
More data are needed on the effects of different NSAIDs on
blood pressure and on relationships with pharmacodynamics,
pharmacokinetics, and dosing regimens of the various
NSAIDs and background antihypertensive therapies. Based
on the data reported so far, it appears that chronic NSAID
therapy can influence blood pressure significantly and that
this may be relevant to cardiovascular event outcomes.
The vascular endothelium and endothelial
mediators
The vascular endothelium is a complex structure that releases
mediators with important paracrine and autocrine effects on
vascular tone and blood pressure, platelet aggregation,
thrombus formation, and atheroma development. NO is one of
many mediators released by the endothelium; others include
prostaglandins (for example, PGI2 and PGH2), endothelin-1,
thromboxane A2, interleukins, bradykinin, angiotensin II, chemo-
kines, nuclear factor-κB, and vascular endothelial growth
factor (Figure 2). These mediators interact to control aspects
such as dilatation/constriction, proliferation, thrombosis, inflam-
mation, permeability, and angiogenesis, all of which contribute
to the health (or disease) of the vascular endothelium. NO
availability has long been used to define endothelial function
and a reduction in NO bioavailability is generally classed as
‘endothelial dysfunction’ although in practice, alterations in
other mediators may also be involved in this state.
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Endothelial dysfunction is present in many disease states,
including diabetes mellitus [54], hyperlipidemia [55], and
hypertension [56], as well as in cigarette smoking [57] and
increasing age [58]. Interestingly, most of these conditions
are considered to be risk factors for cardiovascular disease in
their own right, and many of them tend to cluster together in
the same individuals. Indeed, endothelial dysfunction is a
good surrogate marker or predictor of cardiovascular risk
[59-61] and it is considered by some to be the earliest
detectable sign of atherosclerosis [62,63]. More recently,
endothelial dysfunction has also been identified in inflam-
matory arthritides, including rheumatoid arthritis [64-66],
systemic lupus erythematosus [67,68], psoriatic arthritis [69],
and ankylosing spondylitis [70]. In psoriatic arthritis, the
degree of endothelial dysfunction has been shown to
correlate with disease activity, as assessed using C-reactive
protein (CRP) level and erythrocyte sedimentation rate [69].
In an anterior-cruciate ligament deficient rabbit knee model of
osteoarthritis, there was reduced vascular responsiveness to
acetylcholine in the medial collateral ligament vessels
compared with controls, suggesting that a degree of
endothelial dysfunction may also exist in osteoarthritis [71],
although there is little evidence of this in humans to date.
Several different cardiovascular agents have been shown to
improve endothelial function; interestingly, many of these
have also improved survival or reduced future cardiovascular
events in large outcome trials. For example, statins improve
endothelial function [72] and reduce mortality [73]. Also,
spironolactone improves endothelial function [74] and
reduces mortality in patients with heart failure [75]. Other
examples include aspirin [76] and angiotensin converting
enzyme inhibitors [77]. In most cardiovascular studies nitrates
have not affected survival outcomes, but there are exceptions.
When combined, isosorbide dinitrate and hydralazine therapy
given to African-Americans with heart failure improved
survival significantly compared with placebo [78]. Hydralazine
has antioxidant effects in addition to its blood pressure
lowering effects [79], and it has been suggested that this
may partly account for the favorable outcome in the above
study. However, it is also of note that a meta-analysis [80]
showed that long-term organic nitrate use in patients after
myocardial infarction was associated with higher mortality.
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Figure 2
Vascular endothelial mediators and their effects. Adapted with permission from Lüscher and Barton [115]. Ang, angiotensin; bFGF, basic fibroblast
growth factor; ET, endothelin; ETA/B, endothelin receptor subtype A/B; ICAM, intracytoplasmic adhesion molecule; IL, interleukin; LDL, low-density
lipoprotein; oxLDL, oxidized low-density lipoprotein; MCP, monocyte chemoattractant protein; NO, nitric oxide; NOS, nitric oxide synthase; O2
-,
superoxide; ONOO-, peroxynitrite; PAI, plasminogen activator inhibitor; PDGF, platelet derived growth factor; TGF, transforming growth factor;
TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule.Therefore, it is not possible at present to generalize about
whether NO donors and drugs improving endothelial function
will always improve outcome, because further investigation of
the effects of individual agents is required.
Measurement of endothelial function
There are many ways to measure endothelial function. The
‘gold standard’ method employs venous occlusion plethys-
mography to measure forearm blood flow responses to
intrabrachial arterial infusions of the endothelium-dependent
vasodilator acetylcholine [81]. Usually, the NO-releasing
endothelium-independent vasodilator sodium nitroprusside is
infused as a control, and baseline production of NO by the
endothelium can also be assessed by measuring the
reduction in forearm blood flow after infusion of the NOS
inhibitor L-NMMA. Endothelial function can also be measured
in the coronary arteries, for example during coronary angio-
graphy, again by assessing vascular responses to infusion of
acetylcholine. Other less invasive methods of assessing
endothelial function include flow-mediated dilatation [82,83],
which involves measuring flow responses to brief cuff
occlusion of the brachial artery using ultrasonography, and
using pulse wave analysis to measure responses to the
endothelium-dependent vasodilator salbutamol in comparison
with the endothelium-independent vasodilator GTN [84].
Plasma or serum markers of endothelial function, including N-
acetyl-β-glucosaminidase, E-selectin, P-selectin, and intra-
cytoplasmic adhesion molecule-1, and the presence of
circulating endothelial progenitor cells have also been used
to assess endothelial activity.
Nonsteroidal anti-inflammatory drugs and
endothelial function
In several studies it has been shown that aspirin improves
endothelial function in humans [76,85,86], and this is one of
the mechanisms that has been proposed for its cardio-
vascular protective effect. However, data regarding the
effects of other NSAIDs on endothelial function are less clear.
In one study, diclofenac infusion increased methacholine-
induced vasodilatation measured by venous occlusion
plethysmography only in those with chronic renal failure, but
not in healthy volunteers [87]. In patients with rheumatoid
arthritis, neither indomethacin nor rofecoxib improved flow-
mediated dilatation [88].
Likewise, 8 weeks of rofecoxib therapy in patients with
coronary artery disease had no influence on flow-mediated
dilatation or inflammatory markers [89], but in two other
studies short-term [90] or 6 months of therapy [91] with
rofecoxib led to reductions in CRP and IL-6 levels but no
changes in brachial artery flow-mediated dilatation. In another
study [92], no change in acetylcholine-induced forearm blood
flow response was seen after treatment with either rofecoxib
or naproxen in healthy volunteers. Hence, many of the data
have suggested little effect of these drugs on endothelial
function.
Interestingly, however, parecoxib (prodrug of valdecoxib)
reduced endothelium-dependent vasodilatation in response
to acetylcholine (measured using venous occlusion
plethysmography) in patients with essential hypertension
[93]. Conversely, in a cross-over study of male patients with
severe coronary artery disease, 2 weeks of celecoxib therapy
resulted in greater brachial artery flow-mediated (endo-
thelium-dependent) dilatation compared with placebo.
Celecoxib therapy also reduced high-sensitivity CRP and
oxidized low-density lipoprotein levels [94], suggesting that it
had a positive effect on reducing inflammation and oxidative
stress, although whether this was the mechanism for the
improvement in endothelial function is not clear. Celecoxib
has also been found to improve flow-mediated dilatation in
patients with essential hypertension both acutely and after 1
week of therapy [95]. Whether differing effects of NSAIDs on
endothelial function are directly relevant to the overall
cardiovascular risks attributable to each agent remains to be
determined [61].
Nonsteroidal anti-inflammatory drugs and
platelet function
Aspirin inhibits platelet aggregation by binding irreversibly to
platelet COX-1, inhibiting the production of platelet throm-
boxane for the life of the platelet. Other nonselective NSAIDs
bind reversibly to COX-1 and have variable degrees of
antiplatelet aggregatory effects, depending on the degree of
COX-1 inhibition and the affinity of binding. In addition, some
NSAIDs appear to interfere with the ability of aspirin to bind
to platelet COX-1 and may therefore inhibit the antiplatelet
effects of aspirin in patients taking both together. This may
even negate the influence of low-dose aspirin in cardio-
vascular disease prevention. In a recent study measuring ex
vivo platelet function in healthy volunteers [96], ibuprofen,
naproxen, indomethacin, and tiaprofenic acid were found to
reduce the effect of aspirin on platelets. No apparent
interaction with platelet function was observed between
celecoxib or sulindac and aspirin. Studies have also
suggested a link between co-administration of ibuprofen and
aspirin and reduced cardiovascular disease prevention with
aspirin [97,98]. NO inhibits platelet aggregation via a cGMP-
dependent mechanism, and therefore the co-administration of
NO with NSAIDs could be beneficial in some circumstances
in which inhibition of platelet aggregation is also a goal in a
patient who requires NSAID therapy.
Cyclo-oxygenase inhibiting nitric oxide
donating drugs
Over the past few years, ‘NO-releasing’ NSAIDs have been
developed; in these agents, an NSAID is chemically linked
with a NO moiety [99]. Originally, these were designed to
improve the gastrointestinal side-effect profiles of the
NSAIDs; in particular, it was hoped that they would reduce
ulcer disease and gastrointestinal hemorrhage. However, as
more evidence accumulates about the possible adverse
cardiovascular effects of many of the NSAIDs, the question of
Available online http://arthritis-research.com/supplements/10/S2/S3
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improve the cardiovascular risk profile of patients taking
chronic NSAIDs has arisen. NO is released slowly from the
CINOD, and this is thought to take place in vivo via an
enzymatic esterase based reaction [100]. Various CINODs
have been developed, including NO derivatives of aspirin,
flurbiprofen, naproxen (naproxcinod), diclofenac, and
ibuprofen. Few data are currently available on their effects in
humans.
CINODs have extra effects over and above those of their
parent NSAID. For example, NO-aspirin, unlike standard
aspirin, reduces levels of the proinflammatory cytokine IL-1β
by inhibiting gastric caspase-1 activity [101]. In various
animal models of acute and chronic inflammation, CINODs
have exhibited similar or even greater effects on inhibition of
inflammation to those of their parent NSAIDs [102,103].
Also, a NO-releasing aspirin derivative had a sevenfold more
potent effect on inhibition of platelet aggregation than aspirin
when given to rats [104].
Data on the vascular effects of CINODs show that there is
some influence on vascular tone. In vitro, the CINODs NO-
flurbiprofen and NO-aspirin, and a NO-steroidal compound,
NO-prednisolone, all cause vasorelaxation of rat aortic rings
via a NO-dependent mechanism, with a vasodilator potency
at least three orders of magnitude less than that of sodium
nitroprusside [105]. However, there were no effects on
systemic blood pressure when NO-flurbiprofen or NO-aspirin
were given intravenously to anesthetized rats. When
naproxen or naproxcinod was administered to rats for
4 weeks, the naproxen treated rats had significantly higher
blood pressure than did those treated with naproxcinod or
placebo. In a group of rats pretreated with the NOS inhibitor
L-NAME to induce hypertension, naproxcinod reduced the
blood pressure significantly whereas naproxen alone
increased the blood pressure [106].
The effects of naproxcinod on blood pressure in humans have
been investigated in clinical studies. A 6-week clinical phase
2 study conducted in osteoarthritis patients comparing nap-
roxcinod versus rofecoxib and naproxen [107] showed trends
toward reductions in mean systolic and diastolic blood
pressures with naproxcinod 375 mg and 750 mg twice daily,
as compared with trends towards increased blood pressure
in the rofecoxib and naproxen 500 mg groups. The first phase
3 study with naproxcinod in patients with osteoarthritis [108]
identified small reductions from baseline in mean office
systolic blood pressure with naproxcinod 750 mg twice daily
and in mean office diastolic blood pressure with naproxcinod
375 mg twice daily or 750 mg twice daily, as compared with
naproxen 500 mg twice daily. In an exploratory 24-hour
ambulatory blood pressure monitoring study performed in
hypertensive patients [109], differential effects on blood
pressure of naproxcinod compared with naproxen were also
observed. Although the primary end-point of least square
mean change from baseline in average 24-hour systolic blood
pressure (1.9 mmHg) was not statistically significantly differ-
ent, there was a reduction in the secondary end-point of
average 24-hour diastolic blood pressure of 1.9 mmHg
(P = 0.007) in favor of naproxcinod.
Some of the human data presented thus far reveal non-
significant trends rather than actual differences in blood
pressure. However, even small reductions in blood pressure
may have significant effects on cardiovascular outcome within
the context of chronic therapy with NSAIDs, because it has
been reported that use of many of these agents (including
naproxen, meloxicam, diclofenac, and ibuprofen) results in
average increases in mean arterial pressure as high as
5.5 mmHg [47,110-112]. Further data are required to
evaluate whether there is a true benefit of CINODs on blood
pressure in humans, and such studies are currently ongoing.
The effects of CINODs on endothelial function are not yet
known. Also, it is unclear whether CINODs might be subject
to the development of vascular tolerance in a similar way to
that seen with organic nitrates.
There is also some evidence that CINODs protect the
myocardium from ischemia/reperfusion injury. Using left
ventricular end-diastolic pressure as a surrogate marker for
myocardial dysfunction in an in vitro perfused rabbit heart
model [113], pretreatment with aspirin, celecoxib, or meloxi-
cam increased myocardial damage after ischemic insult and
reperfusion. However, pretreatment with NCX-4016 (an NO-
releasing aspirin derivative) had the opposite effect,
reducing myocardial damage and dysfunction caused by the
insult. In a similar study [114], in dose-related manners,
naproxen increased ischemia/reperfusion injury compared
with vehicle whereas naproxcinod reduced ischemia/
reperfusion injury.
It is potentially the case that some of the cardiovascular risk
associated with chronic NSAID use may be ameliorated by
steady donation of NO in the vasculature. However, further
work in humans is necessary to investigate this potential.
Conclusions
Osteoarthritis is a common and disabling disease that is
becoming more prevalent as our population ages. Partly as a
result of its association with increased age, many patients
being treated for osteoarthritis will also have risk factors for
cardiovascular disease. Therefore, the remit of future treat-
ment strategies for osteoarthritis must broaden from simply
managing joint pain to take into account the overall
management of the patient as well, along with any co-existing
risk factors. We must also carefully consider the risks for
gastrointestinal, cardiovascular, and other adverse effects of
all drug therapies. Both traditional NSAIDs and COX-2
selective NSAIDs have been associated with increased
cardiovascular risk, but many patients with osteoarthritis rely
on these medications to achieve adequate symptomatic
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cardiovascular risks associated with NSAIDs would be
welcome.
NO is a key regulator of vascular function in health and
disease with effects on vascular tone, platelet function, and
endothelial function. The donation of extra NO by pharma-
ceutical agents is a possible means of influencing vascular
function and cardiovascular outcomes. The recently developed
CINODs represent an exciting new class of agent that show
promise in the pharmacological management of the pain
associated with osteoarthritis, being at least as effective as
NSAIDs in animal studies to date. They have also shown
some potential for being more effective, given the effects of
NO on pain perception, while also offering additional benefits
such as increased gastric protection. This may improve pain
control in osteoarthritis. At the same time, previous data have
suggested that some of the joint damage in osteoarthritis has
been mediated by NO; this therefore requires further
investigation in humans. However, turning once again to the
broader cardiovascular perspective, there may be some overall
advantages of these compounds in the management of
osteoarthritis. Theoretically, CINODs may influence endo-
thelial function, vascular tone, and other surrogate markers of
cardiovascular risk. If this were shown to reduce the
incidence of cardiovascular events in patients taking chronic
NSAID therapy, then this would be a major breakthrough in
the management of arthritis in general. Further studies to
investigate the effects of CINODs on blood pressure,
vascular function, and structure will guide their future use in
humans.
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